Nav: Home

Lithium boosts muscle strength in mice with rare muscular dystrophy

June 03, 2019

Standing up from a chair, climbing stairs, brushing one's hair - all can be a struggle for people with a rare form of muscular dystrophy that causes progressive weakness in the shoulders and hips. Over time, many such people lose the ability to walk or to lift their arms above their heads.

This form of the disease - called limb girdle muscular dystrophy - affects a few thousand people nationwide. Like other rare illnesses, it tends not to attract much attention from researchers and funding agencies, so progress toward developing therapies has been slow. But a team at Washington University School of Medicine in St. Louis that identified a subtype of the disease in 2012 has shown that lithium improves muscle size and strength in mice with this form of muscular dystrophy. The findings, published April 18 in Neurology Genetics, could lead to a drug for the disabling condition.

"There are no medications available for people with limb girdle muscular dystrophy, so we are very excited to have a good therapeutic target and a potential therapy," said senior author C. Chris Weihl, MD, PhD, a professor of neurology who treats people with muscular dystrophy at the university's Neuromuscular Disease Center. "This has been an amazing project. It all began when we diagnosed a patient with muscular dystrophy of unknown cause. Genetic sequencing then helped us identify a new subtype, and we've been able to take that all the way through to a possible therapy."

Limb girdle muscular dystrophy can be caused by variations in any one of more than a dozen different genes. Several years ago, Weihl and colleagues - including neurologists Robert Baloh, MD, PhD, and Matthew Harms, MD - identified two families in which several members had symptoms of the condition but none of the known genetic variants. By analyzing the DNA of affected and unaffected members of both families, the researchers found that a variation in the gene DNAJB6was responsible for their muscle weakness.

While the researchers had found the faulty gene, it wasn't immediately clear why an alteration to that gene caused people's muscles to atrophy. To find out, Weihl and co-first authors Andrew Findlay, MD, a clinical fellow in neurology, and Rocio Bengoechea Ibaceta, PhD, a staff scientist, cut the gene out entirely, expecting to see even more muscle loss when the gene was absent.

They found the opposite: Without DNAJB6, muscle fibers grew to three times their normal size.

"When Drew showed me these enormous muscle fibers, I just didn't understand it," Weihl said. "But Drew pointed out that we were on the right pathway, but perhaps going the wrong direction. Something in this pathway is important for muscle growth."

The researchers tried again, this time using genetically modified mice that Weihl and colleagues had engineered in 2015. These mice carried the same genetic variant as the patients, and like the patients, they developed progressive muscle weakness in adulthood. Using muscle from these mice, the researchers discovered that disease variants overactivate a protein that suppresses muscle growth. Moreover, inhibiting the protein - called GSK3beta - with lithium chloride improves mice's strength and muscle mass.

"Before treatment, mutant mice had roughly one-fifth the strength of the normal mice," Findlay said. "After a month of treatment, they improved to 75 percent of the normal mice. It's a big jump."

Lithium chloride was once sold as table salt but was taken off the shelves in 1949, when doctors realized that sprinkling it liberally on food can be deadly. But other forms of lithium such as lithium carbonate and lithium citrate are used to treat some psychiatric illnesses, so it's possible a safe form of lithium can be found to treat the rare muscular dystrophy.

"I don't want people to go out and take lithium chloride right now," Findlay said. "We've shown that this protein is a promising therapeutic target, but more work needs to be done."

Before any compound targeting the protein is tested in humans, a better understanding of limb girdle muscular dystrophy is needed. The disease is so rare that doctors have not defined how quickly different people lose strength and how the course of the disease differs in people whose condition is caused by variations in different genes.

"We're at a point where therapeutic development has outpaced our understanding of the natural history of this disease," Weihl said. "We have a therapeutic target, but we don't fully understand how patients progress when they're not treated. We need to understand as many people with this rare disease as possible so when we do start testing an investigational drug, we can be confident that it is changing the course of the disease."

Weihl, Findlay, and colleagues around the U.S. and U.K. are planning a study of people with limb girdle muscular dystrophy caused by variations in any gene. The study will map disease progression in such people in preparation for upcoming treatment trials. Participants will make annual visits to the neuromuscular clinic to undergo functional assessments such as timed stair climbs and fill out questionnaires rating their ability to perform tasks of daily life.
-end-


Washington University School of Medicine

Related Muscular Dystrophy Articles:

Designed proteins to treat muscular dystrophy
The cell scaffolding holds muscle fibers together and protects them from damage.
Gene-editing alternative corrects Duchenne muscular dystrophy
Using the new gene-editing enzyme CRISPR-Cpf1, researchers at UT Southwestern Medical Center have successfully corrected Duchenne muscular dystrophy in human cells and mice in the lab.
GW researcher finds genetic cause of new type of muscular dystrophy
George Washington University & St. George's University of London research, published in The American Journal of Human Genetics, outlines a newly discovered genetic mutation associated with short stature, muscle weakness, intellectual disability, and cataracts, leading researchers to believe this is a new type of congenital muscular dystrophy.
Not all Europeans receive the same care for Duchenne muscular dystrophy
Duchenne muscular dystrophy (DMD), a progressive muscle disease affecting one in 3,800-6,300 live male births and leads to ambulatory loss, respiratory problems, cardiomyopathy, and early death of patients in their 20s or 30s.
A vitamin could help treat Duchenne muscular dystrophy
Researchers are working on a new strategy to combat one of the most severe forms of muscular dystrophy.
New research increases understanding of Duchenne muscular dystrophy
A new paper, co-written by faculty at Binghamton University, State University of New York, increases the understanding of Duchenne muscular dystrophy (DMD) -- one of the most common lethal genetic disorders -- and points to potential therapeutic approaches.
Cause of heart arrhythmia in adult muscular dystrophy clarified
An international joint research group found that the cause of heart arrhythmia in myotonic dystrophy was RNA abnormalities in the sodium channel in the heart, clarifying the symptom's mechanism.
New muscular dystrophy drug target identified
Scientists at the University of Liverpool have discovered that muscle cells affected by muscular dystrophy contain high levels of an enzyme that impairs muscle repair.
New insights into muscular dystrophy point to potential treatment avenues
Certain stem cells in our bodies have the potential to turn into either fat or muscle.
Decoding sugar molecules offers new key for combating muscular dystrophy
A group of Japanese scientists have succeeded in decoding a sugar molecule and clarifying a mechanism linked to muscular dystrophy.

Related Muscular Dystrophy Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Anthropomorphic
Do animals grieve? Do they have language or consciousness? For a long time, scientists resisted the urge to look for human qualities in animals. This hour, TED speakers explore how that is changing. Guests include biological anthropologist Barbara King, dolphin researcher Denise Herzing, primatologist Frans de Waal, and ecologist Carl Safina.
Now Playing: Science for the People

#532 A Class Conversation
This week we take a look at the sociology of class. What factors create and impact class? How do we try and study it? How does class play out differently in different countries like the US and the UK? How does it impact the political system? We talk with Daniel Laurison, Assistant Professor of Sociology at Swarthmore College and coauthor of the book "The Class Ceiling: Why it Pays to be Privileged", about class and its impacts on people and our systems.